Back to Search
Start Over
Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
- Source :
-
European heart journal [Eur Heart J] 2019 Nov 21; Vol. 40 (44), pp. 3605-3612. - Publication Year :
- 2019
-
Abstract
- Aims: Although loop diuretics are widely used to treat heart failure (HF), there is scarce contemporary data to guide diuretic adjustments in the outpatient setting.<br />Methods and Results: In a prospective, randomized and double-blind protocol, we tested the safety and tolerability of withdrawing low-dose furosemide in stable HF outpatients at 11 HF clinics in Brazil. The trial had two blindly adjudicated co-primary outcomes: (i) symptoms assessment quantified as the area under the curve (AUC) of a dyspnoea score on a visual-analogue scale evaluated at 4 time-points (baseline, Day 15, Day 45, and Day 90) and (ii) the proportion of patients maintained without diuretic reuse during follow-up. We enrolled 188 patients (25% females; 59 ± 13 years old; left ventricular ejection fraction = 32 ± 8%) that were randomized to furosemide withdrawal (n = 95) or maintenance (n = 93). For the first co-primary endpoint, no significant difference in patients' assessment of dyspnoea was observed in the comparison of furosemide withdrawal with continuous administration [median AUC 1875 (interquartile range, IQR 383-3360) and 1541 (IQR 474-3124), respectively; P = 0.94]. For the second co-primary endpoint, 70 patients (75.3%) in the withdrawal group and 77 patients (83.7%) in the maintenance group were free of furosemide reuse during follow-up (odds ratio for additional furosemide use with withdrawal 1.69, 95% confidence interval 0.82-3.49; P = 0.16). Heart failure-related events (hospitalizations, emergency room visits, and deaths) were infrequent and similar between groups (P = 1.0).<br />Conclusions: Diuretic withdrawal did not result in neither increased self-perception of dyspnoea nor increased need of furosemide reuse. Diuretic discontinuation may deserve consideration in stable outpatients with no signs of fluid retention receiving optimal medical therapy.<br />Clinicaltrials.gov Identifier: NCT02689180.<br /> (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Subjects :
- Aged
Body Fluids physiology
Brazil epidemiology
Case-Control Studies
Double-Blind Method
Dyspnea diagnosis
Dyspnea psychology
Female
Follow-Up Studies
Furosemide administration & dosage
Heart Failure physiopathology
Humans
Male
Middle Aged
Prospective Studies
Safety
Self Concept
Sodium Potassium Chloride Symporter Inhibitors administration & dosage
Time Factors
Treatment Outcome
Ventricular Function, Left drug effects
Visual Analog Scale
Furosemide therapeutic use
Heart Failure drug therapy
Sodium Potassium Chloride Symporter Inhibitors therapeutic use
Withholding Treatment statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1522-9645
- Volume :
- 40
- Issue :
- 44
- Database :
- MEDLINE
- Journal :
- European heart journal
- Publication Type :
- Academic Journal
- Accession number :
- 31424503
- Full Text :
- https://doi.org/10.1093/eurheartj/ehz554